All Activity

“Right now we’re testing inactive metabolites, mostly through urine, and it’s really not accurate. The inactive metabolites don’t show impairment, it just shows whether or not you used it [in the past].” By Jake Zuckerman, Signal Cleveland This story was originally published by Signal Cleveland. Sign up for their free newsletters at SignalCleveland.org/subscribe. The Ohio Senate unanimously passed legislation last week to overhaul the way that prosecutors must prove whether a person was driving under the influence of marijuana. Ohio, like most the rest of the nation, has liberalized its marijuana laws over the past decade, now allowing recreational and medical use of the drug in a variety of forms. This has posed a tricky challenge of setting a legal standard that prohibits driving while under the influence of marijuana, while not ensnaring people who are sober on the road but have used the drug in the past few days. And unlike with alcohol’s well established limit of .08 percent of blood alcohol content as the legal threshold for impaired driving, the science around cannabis concentration in the blood is far murkier. Some people with high concentrations wouldn’t exhibit behavioral signs of impairment, while some people with low concentrations would, studies show. “The current law allows for the conviction of innocent people, 100 percent straight out,” said Tim Huey in an interview, who lobbied for the bill on behalf of fellow DUI defense attorneys. What the bill would do for drivers of accused of being high Senate Bill 55, if agreed to by the Ohio House and the governor, would bring two big changes for people accused of driving while high. For one, it ends prosecutors’ current ability to convict drivers for driving under the influence based solely on the presence of marijuana “metabolites” in a person’s system. Metabolites are the non-psychoactive byproduct of marijuana produced as the body breaks down (metabolizes) marijuana. Those metabolites can linger in a person’s system as long as 30 days after use, according to researchers and defense attorneys who support the bill. Instead, police and prosecutors must show the presence of Delta 9-THC, the active ingredient that produces the high sensation. The legislation also gives people accused of driving while high an opportunity to rebut the evidence against them if a comparatively lower concentration of marijuana is detected in their systems. That’s opposed to the “per se” system in current law, where a positive drug test almost guarantees a conviction. “Basically right now we’re testing inactive metabolites, mostly through urine, and it’s really not accurate,” said Sen. Nathan Manning, a Lorain County Republican and former prosecutor who has pushed the legal change for years. “The inactive metabolites don’t show impairment, it just shows whether or not you used it [in the past].” Several sources described the legal thresholds set in the legislation as the product of more art than science, and a compromise between prosecutors and defense attorneys who lobbied the bill. Half baked? Ohio legalized marijuana for medicinal use in 2019 and for adult recreational use in 2023, joining a list of 37 other states that allow some form of legal marijuana use. Senate Bill 55 would be the first major update to the marijuana DUI laws since then. The roadways pose one of the biggest risk zones for a newly legalized intoxicating substance. Marijuana has been associated with slower reaction times, difficulty maintaining lane positioning, divided attention and other behaviors that worsen driving performance. The problem, as noted in a 2017 National Highway Transportation Safety Administration research review, is that available evidence shows a weak correlation between blood THC concentration and measurable impairment. The AAA Foundation for Traffic Safety in 2016 conducted a similar study and found that per se laws like Ohio’s “cannot be scientifically supported.” While the organization opposes the legalization of marijuana due to what it describes as negative traffic safety implications, it opposes any per se DUI law unless prosecutors pair it with behavioral evidence of impairment like weaving between lanes or bloodshot eyes. Legislation calls for THC testing, new thresholds The proposed law still allows for per se convictions of marijuana. However, it raises that threshold from 2 nanograms per milliliter of blood to 5 ng/ml. In other words, a drug test detecting higher than that will yield a guaranteed conviction, assuming no legal roadblocks arise. For those with concentrations of 2- to 5 ng/ml, juries and judges can “infer” that a driver was impaired. However, that driver can introduce evidence, summon witnesses, or testify on their own behalf to rebut that inference. The new standard doesn’t absolutely rule out the possibility of a false positive, according to Alfred Staubus, a pharmacist and forensic toxicologist, However, he said in an interview that ending a legal system where the presence of marijuana metabolites can automatically trigger a conviction is a massive step forward. “If you have it much higher than [5 ng/ml], then there will be a large group of people that are impaired that will not be convicted on a per se charge,” he said. “If you have it down to 2, then there’s going to be a large group of people that are not impaired but will be convicted.” Prosecutors disagree The Ohio Prosecuting Attorneys Association has successfully thwarted similar legislation over the past few years. This time around, the prosecutors declined to formally oppose the bill in committee. Lou Tobin, the association’s executive director, said in an email that Manning, the sponsor, made changes the prosecutors asked for including maintaining a per se threshold for THC concentration in blood, and including various THC-knockoff products like Delta-8 THC (a similar product that has avoided regulation via a legal loophole). He disputed the notion that testing for metabolites produces false positive convictions. “People aren’t being randomly pulled over and subjected to urine tests,” he said. “They’re pulled over because the officer had some reason to suspect that they were driving impaired and then their urine is tested because there was probable cause that confirmed the suspicion.” He said the prosecutors would be fine with a zero tolerance approach to any level of THC in the bloodstream. But keeping at least some limit, as the bill does, acts as a deterrence. Plus, he noted that the law still allows for OVI convictions for those who show signs of impairment while driving or speaking with officers. “Someone who has used marijuana recently should assume the risks of that if they get behind the wheel,” he said. The post Ohio Senate Passes Marijuana DUI Bill Aimed At Protecting Drivers Who Aren’t High Behind The Wheel From Prosecution appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I was reading some of your content on this website and I conceive this internet site is really informative ! Keep on putting up. 레플리카

Wonderful blog post, resolved to go on and even bookmarked your webblog. As i can’t hold on to enjoy a book alot more as a result of one. Loft conversion prices London

Two prominent progressive members of Congress joked about marijuana at a televised town hall meeting on Wednesday, with one making sure to say that it should be legalized in more states across the country. Sen. Bernie Sanders (I-VT), speaking at the CNN-hosted event, made a cannabis quip while rejecting calls from some Republicans to end the federal government shutdown ahead of negotiations on healthcare issues. “No. Based on their history, they have had months and months. This is not a new thing,” Sanders said. “Ever since Trump’s ‘Big Beautiful Bill’ was passed, we knew this was happening.” “And anyone who thinks that tomorrow they’ll suddenly start negotiating, I think, is smoking what is illegal in many states,” he said, referring to marijuana. Rep. Alexandria Ocasio-Cortez (D-NY) chimed in to say that cannabis “should be legal in more” states. Sanders: They have refused to negotiate. And anyone thinks that tomorrow they'll suddenly start negotiating. I think, is smoking what is illegal in many states AOC: And should be legal in more. pic.twitter.com/tSdEtlnMcy — Acyn (@Acyn) October 16, 2025 Both lawmakers have long supported efforts to reform cannabis policies. During his 2016 campaign, Sanders became the first major presidential candidate to endorse marijuana legalization. He also filed the first-ever Senate bill to end federal cannabis prohibition. Sanders’s 2020 campaign released a marijuana reform plan outlining steps he would take to end federal cannabis prohibition and ensure that the industry is equitable. At one point the independent senator said that he would use executive action to federally legalize marijuana in all 50 states on the first day of his presidency. Ocasio-Cortez, for her part, has voted in favor of bills to federally legalize cannabis on the House floor and has sponsored legislation to incentivize the expungement of cannabis convictions at the state level. In an interview with Marijuana Moment earlier this year, she criticized the anti-cannabis views of the Trump administration’s acting head of the Drug Enforcement Administration, saying that if he is so concerned about potential health risks from cannabis, “then maybe he should deschedule marijuana so it can be freely studied.” “Does he have a medical degree? He doesn’t even have a medical degree,” the congresswoman said, adding that “we can also learn from states that have not criminalized marijuana but have treated it as a substance, the same as alcohol and many other substances as well.” Last year Ocasio-Cortez suggested that President Donald Trump, who was then running for his current term in office, might be faking his stated support for cannabis reform. His stance in favor of federal rescheduling and industry banking access “sounds like a Hail Mary to me,” she told Marijuana Moment, adding, “I don’t think he’s serious” about the position. The post Bernie Sanders And AOC Joke About Marijuana At Nationally Televised Town Hall Meeting appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thanks with regard to publishing this type of excellent post! I discovered your site ideal for my personal requirements. It has fantastic as well as useful articles. Continue the great function! Loft conversion prices London

Florida medical marijuana officials are actively revoking the registrations of patients and caregivers with drug-related criminal records. The policy is part of broad budget legislation signed into law earlier this year by Gov. Ron DeSantis (R). The provisions in question direct the state Department of Health (DOH) to cancel registrations of medical marijuana patients and caregivers if they’re convicted of—or plead guilty or no contest to—criminal drug charges. The measure says a patient or caregiver will have their registration immediately suspended upon being charged with a covered state drug crime, and the suspension will remain in place until the criminal case reaches a final disposition. DOH officials have authority to reinstate the registration, revoke it entirely or extend the suspension if needed. Bobbie Smith, director of the Florida Office of Medical Marijuana Use (OMMU), told lawmakers on Wednesday that regulators are already banning people from the medical cannabis program under the new policy. OMMU has “identified 20 individuals that meet the new requirement for revocation, and there’s roughly 140 that we’re still monitoring as they wait make their way through the criminal justice system,” she said at a hearing of the House Health Professions & Programs Subcommittee in comments first reported by Florida Politics. Under the law, authorities are required to revoke a person’s registration if the patient or caregiver “was convicted of, or pled guilty or nolo contendre to, regardless of adjudication, a violation [of state drug law] if such violation was for trafficking in, the sale, manufacture, or delivery of, or possession with intent to sell, manufacture, or deliver a controlled substance.” The enacted version of the legislation focuses specifically on production and distribution. It does not contain an earlier restriction from prior versions that would have also revoked registrations for people who merely purchased illegal drugs, including more than 10 grams of marijuana for their own use. It also clarifies that patients and caregivers have a process to request their registrations be reinstated. That involves submitting a new application “accompanied by a notarized attestation by the applicant that he or she has completed all the terms of incarceration, probation, community control, or supervision related to the offense.” It’s not clear from the plain language of the revised bill whether it will impact only future criminal cases involving medical marijuana patients and caregivers or whether DOH would need to review the records of existing program registrants and revoke registrations of an untold number of Floridians with past drug convictions. Florida lawmakers defeated several proposals to expand the medical cannabis program during this year’s regular legislation session—including by allowing home cultivation, adding new qualifying conditions, protecting employment and parental rights of patients and letting military veterans register for free. Meanwhile, DeSantis recently acknowledged in a speech that marijuana legalization is popular with voters even though he opposes it and campaigned to defeat a reform initiative on the state’s ballot last year. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Advocates are now working on a new cannabis initiative that they hope to place on Florida’s 2026 ballot. As of this summer, the renewed legalization campaign has collected more than 75 percent of the required signatures to put the marijuana measure before voters next year, according to state officials. DeSantis said in February that the newest proposal is in “big time trouble” with the state Supreme Court, predicting it will be blocked from going before voters next year. Smart & Safe Florida is hoping the revised version will succeed in 2026. The campaign—which in the last election cycle received tens of millions of dollars from cannabis industry stakeholders, principally the multi-state operator Trulieve—incorporated certain changes into the new version that seem responsive to criticism opponents raised during the 2024 push. For example, it now specifically states that the “smoking and vaping of marijuana in any public place is prohibited.”Another section asserts that the legislature would need to approve rules dealing with the “regulation of the time, place, and manner of the public consumption of marijuana.” Last year, the governor accurately predicted that the 2024 cannabis measure from the campaign would survive a legal challenge from the state attorney general. It’s not entirely clear why he feels this version would face a different outcome. While there’s uncertainty around how the state’s highest court will navigate the measure, a poll released in February showed overwhelming bipartisan voter support for the reform—with 67 percent of Florida voters backing legalization, including 82 percent of Democrats, 66 percent of independents and 55 percent of Republicans. However, the results conflict with another recent poll from the Florida Chamber of Commerce, a proactive opponent of legalization, that found majority support for the reform among likely voter (53 percent) but not enough to be enacted under the 60 percent requirement. Another recent poll of Florida Republican voters showed just 40 percent of that demographic said they’d vote in favor of the legalization proposal. In the background of the campaign’s signature development, DeSantis signed a GOP-led bill in June to impose significant restrictions on the ability to put initiatives on the ballot—a plan that could impair efforts to let voters decide on marijuana legalization next year. Meanwhile in Florida, a state senator recently filed a pair of bills for the 2026 legislative session that would provide employment and parental rights protections for registered medical marijuana patients. The post Florida Officials Are Revoking Medical Marijuana IDs From Patients And Caregivers With Drug Convictions Under Law Signed By DeSantis appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

OK legalization ballot deadline; Fed VA official on psychedelics; Marijuana advocacy org urges industry collab; Study: Cannabis as opioid alternative Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Subscribers who value this daily dispatch enough to show their support with a few dollars help us keep doing this. Please chip in and help ensure Marijuana Moment’s continued operations. https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW New FBI data shows that at least 200,000 people were arrested for marijuana in the U.S. last year—the vast majority for possession—even as advocates point out the report’s methodology likely significantly understates the scope of cannabis and drug enforcement. A Department of Veterans Affairs mental health official said the federal government needs to “gear up” to provide psychedelic medicines to military veterans and ensure that therapists are equipped to facilitate the novel treatments. Oklahoma marijuana activists have less than three weeks left to collect enough valid signatures to qualify a legalization initiative for the 2026 ballot, and more than 500 locations across the state—from medical cannabis dispensaries to tattoo parlors—are hosting petitions that voters can sign. The Marijuana Policy Project sent an open letter to cannabis business leaders making the case that the industry and independent pro-reform activist groups “need each other” at a time when a “resurgent and well-funded neo-prohibitionist movement” is rising. “Neither industry nor advocacy will succeed alone.” A new study found legalizing medical marijuana is “associated with significant reductions in opioid prescribing.” “These findings support the potential of [medical cannabis laws] as a policy tool for reducing opioid use and promoting safer pain management.” An Ohio judge issued a temporary restraining order preventing Gov. Mike DeWine’s (R) executive order to ban intoxicating hemp product sales from taking effect while litigation proceeds. The Missouri Division of Cannabis Regulation is proposing new rules that would let marijuana dispensaries offer curbside pickup, in addition to drive-thru and delivery services that are already allowed. / FEDERAL Former Department of Government Efficiency head Elon Musk is calling on the federal government to send troops to San Francisco, California to address what he called a “drug zombie apocalypse.” The House bill to federally legalize marijuana got one new cosponsor for a total of 56. / STATES California Gov. Gavin Newsom (D) vetoed a bill that would have allowed municipalities to impose liens to enforce fines and penalties related to unlicensed commercial cannabis activities. Members of the Maryland Senate Finance Committee toured marijuana cultivation and processing facilities. An Arizona judge dismissed a lawsuit claiming that Gov. Katie Hobbs (D) and her chief of staff worked to improperly award a marijuana dispensary license. A Florida grand jury is taking testimony ahead of potential prosecutions concerning the alleged misuse of Medicaid settlement funds to campaign against a marijuana legalization ballot initiative. Washington, D.C. regulators are asking a federal court to dismiss a lawsuit challenging the city’s marijuana rules. Oregon regulators published resources on cannabis use while pregnant, lactating or caring for young children. Michigan regulators published a monthly report on disciplinary actions against marijuana businesses. New Jersey officials marked the one-year anniversary of the Cannabis Training Academy. The Maryland Cannabis Public Health Advisory Council will meet on Thursday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Oakland, California Cannabis Regulatory Commission will meet on November 6. / INTERNATIONAL Colombian President Gustavo Petro said he will “regulate the legal use of cannabis for non-recreational purposes” given the passage of a United Nations Human Rights Council drug policy resolution. / SCIENCE & HEALTH A study found that “medicinal cannabis presents a complex yet promising solution for reducing opioid-related mortality and addressing healthcare inequities.” A study found that medical cannabis “may improve [quality of life] for cancer patients by alleviating physical and psychosocial symptoms associated with cancer treatment.” / ADVOCACY, OPINION & ANALYSIS The Colorado Springs Gazette editorial board claimed that marijuana legalization is causing “carnage on our highways.” / BUSINESS New Instagram rules for teen accounts will hide or not recommend posts that “could encourage potentially harmful behaviors, such as posts showing marijuana paraphernalia.” Vireo Growth Inc. closed a transaction to acquire outstanding senior secured convertible notes of Medicine Man Technologies Inc. Canopy Growth Corporation shareholders elected board of directors members. Michigan retailers sold $251.3 million worth of legal marijuana products in September. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post FBI data shows cannabis arrests are driving the drug war (Newsletter: October 16, 2025) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Steal a Brainrot is a fun, chaotic multiplayer Roblox loot game developed by Brazilian Spyder where you collect quirky Brainrot meme characters by m from other players.

The developers of Melon Sandbox really nailed the balance between simplicity and depth.

Every update in BitLife feels like opening a new chapter in your favorite book. There’s always something new to discover — whether it’s fresh challenges, new careers, or interesting relationship dynamics.

Pips NYT is one of those games that looks deceptively simple. It’s not about speed, but about thinking ahead and making every move count — a great exercise in patience and planning.

111. Trip Report: Kanna vs. MDMA Plus How Molly Effs With Your Sleep For Weeks What if you could feel more connected, relaxed, and joyful—without alcohol or MDMA? In this episode, I talk to Andrew Weisse, founder of getKanna and writer of Substack's The Psychedelic Blog, about the mood-enhancing, heart-opening power of Kanna, a South African plant that’s gaining popularity as a functional empathogen. We discuss its chemical makeup, traditional use, and modern applications for social connection, romantic intimacy, and MDMA replacement. This is a big one for anyone exploring a sustainable way to engage with psychedelics. Key Takeaways - Kanna enhances emotional openness, connection, and calm without a crash or sleep disruption - It’s a serotonin reuptake inhibitor, not a psychedelic—legal and gentle - Unlike MDMA, Kanna is non-depleting and can be taken more regularly - April shares her sober-in-Seattle story with Kanna as her “plus one” - Andrew offers insights on sourcing, dosing, and why alcohol-free connection is the future Learn more about this episode, including guests and resources on Substack: https://aprilpride.substack.com/p/mdma-vs-kanna-trip-report-with-andrew-weisse-the-psychedelic-blog Hosted by April Pride Featuring Andrew Weisse, getKanna and The Psychedelic Blog Subscribe for April’s newsletter on Substack at https://aprilpride.substack.com/subscribe or at getsetset.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow on IG: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset Get full access to SetSet with April Pride at aprilpride.substack.com/subscribeCatch the full episode here

Nearly 188,000 people were arrested over marijuana possession in the U.S. last year, according to the FBI’s latest annual crime report, and another 16,000 were booked for allegedly selling or growing cannabis. However, those figures are likely understated given inconsistencies in the federal data and questions about the agency’s methodology. The full 2024 data set is based on more than 14 million criminal offenses reported to the Uniform Crime Reporting (UCR) Program, which is used to document and analyze national crime trends. The report covers 95.6 percent of the U.S. population, FBI said. This latest data does show that cannabis-related offenses fell slightly compared to 2023, dropping from 200,306 possession busts to 187,792 in 2024 and from 16,844 sales or manufacturing arrests to 16,244. Advocates see the reduction as a reflection of the success of the expanding state-level legalization movement, but they also point out that marijuana is still the illegal substance that Americans are most arrested for possessing in the ongoing “war on drugs.” “While the total number of marijuana-related arrests have fallen nationwide in recent years, it is clear that marijuana-related prosecutions still remain a primary driver of drug war enforcement in the United States,” NORML Deputy Director Paul Armentano told Marijuana Moment. Of all drug possession arrests in the new report 27 percent were for marijuana—more than for any other specifically listed substance. Because not all agencies provide complete data for the reporting periods, FBI has explained that the bureau calculates estimated crime numbers, essentially extrapolating “by following a standard estimation procedure using the data provided.” In terms of total reported arrests for a category labelled “drug/narcotic,” for example, FBI said there were 831,446 arrests. At the same time, frustrations over FBI’s inconsistent data reporting on cannabis and other drug arrest trends have persisted. Various sections of the report provide different numbers for seemingly similar categories of offenses. One FBI table says that there were 1,413,223 “Drug/Narcotic Offenses” in 2024. Another uses the figure for 1,577,175 under the same heading. A third puts the total at 1,870,804. Another section says there were 822,488 arrests for drug abuse violations in 2024, accounting for about 12 percent of the approximately 7.5 million estimated arrests nationwide. The FBI data also shows trends over time, indicating that there were 1,055,013 drug offenses charged in 2015 and 600,400 drug offenses charged in 2024—a reduction of about 43 percent, though it’s not clear how much of the change is due to the agency’s shifting methodology for reporting arrests and how much is due to actual changes in enforcement practices and state drug laws over the past decade. In terms of controlled substances seized in 2024, the agency said were 386,540 marijuana seizures out of 1,072,704 total drug seizures, representing about 36 percent of enforcement actions. FBI’s arrest data is widely relied on by lawmakers, researchers and media to understand and contextualize law enforcement trends. Any inconsistencies influence not just the public’s understanding of crime and law enforcement, but also potentially how policy is crafted and implemented. Apparent errors in FBI marijuana were pointed out to the bureau in May 2022, when a longtime drug reformer and former congressional staffer, Eric Sterling, claimed to have discovered that a Maryland police department was reporting cannabis possession citations issued under the state’s decriminalization law at the time as arrests as part of a data-sharing partnership with FBI. Since other state and local law enforcement agencies appear to not be reporting cannabis citations as arrests, Sterling reasoned, the inconsistent practice could significantly alter FBI’s annual reports—making it harder to draw reasonable policy conclusions from the data. In 2023—about 14 months after Sterling sent the inquiry—the office finally replied. Rather than address the apparent problem, however, the Department of Justice’s (DOJ) Office of the Inspector General’s investigations division said it had “determined that the matters that you raised are more appropriate for review by another office within the DOJ” and referred the inquiry to FBI’s own inspection division. FBI’s cannabis enforcement reporting is also compromised by the fact that local and state police are not required to share data to inform the agency’s annual report, meaning it offers an incomplete overview of national law enforcement activities. The agency itself says that certain data may not be comparable to previous years because of different levels of participation over time. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, the Drug Enforcement Administration (DEA) said in a recent filing that the marijuana rescheduling process remains stalled at the stage it has been on for months, despite the head of agency’s prior commitment to senators that he would prioritize the issue if confirmed for the role. President Donald Trump said in August that he intended to make a decision on the proposal to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA) within weeks. Rescheduling would not federally legalize marijuana, however, so it remains to be seen how such a reform might impact arrest rates included in the FBI’s future annual reports. The post More Than 200,000 People Were Arrested For Marijuana In The U.S. Last Year, FBI Data Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A leading marijuana reform advocacy organization is circulating an open letter to the cannabis industry, stressing that the two pillars of the community “need each other” at a time when a “resurgent and well-funded neo-prohibitionist movement” is on the rise. “Neither industry nor advocacy will succeed alone,” the letter from Marijuana Policy Project (MPP) Executive Director Adam Smith says. While some industries concoct seemingly grassroots campaigns to create the appearance of credibility, that “fake grass” is “inorganic, doesn’t grow, nourishes nothing, and is made of mostly forever plastics and noxious chemicals,” Smith wrote. But it’s a different story for the cannabis reform movement. “Cannabis advocacy is not astroturf. It wasn’t created by an industry. In fact, just the opposite,” Smith said, referring to the fact that the movement’s successes created the opportunity for the legal marijuana industry to later emerge. “Cannabis policy reform is a movement. And like every fight for justice, ours was born out of suffering: the suffering of people whose liberty, children, homes, education, or lives were stolen from them in the name of the war on drugs.” “The suffering of those desperate for medicine for themselves or to help a loved one to eat, ease pain, or calm seizures,” he said. It rose against a drug war machine that has fueled government overreach, mass incarceration, discrimination, and inequity for nearly a century. All based on lies told about a plant.” There’s been some tension between the advocacy and industry sides of the cannabis movement in recent years, especially as philanthropic support for grassroots organizations has dried up as a majority of states have moved to legalize marijuana for medical or adult use. It’s an issue that a former MPP executive, Matthew Schweich, routinely discussed as the group fought against the changing policy and financial dynamics. Smith is hoping that his letter will restart the conversation and impress upon the industry that there are mutual benefits to working more closely together in the pursuit of reform. “Industry and advocacy are fighting for the same big goal; not just to end cannabis prohibition, but to end it well,” Smith told Marijuana Moment on Wednesday. “Patients and consumers need safe, dependable access, which requires an economically stable industry that is rationally regulated, reasonably taxed, and operating within a normalized commercial environment.” In an open letter to the cannabis industry, MPP's Executive Director, Adam J. Smith, makes the case that robust independent advocacy is indispensable to industry's goals, and calls for a more strategic deployment of our collective political capital. https://t.co/1hg5VOpKwP — Marijuana Policy Project (@MarijuanaPolicy) October 15, 2025 “But the cannabis issue is about more than dollars and cents, and industry won’t get there alone. Independent advocacy has been and remains an indispensable force for reform,” he said. “We may not agree or collaborate on everything, but we can do a much better job of big picture strategic coordination, and we have to start now.” Because prohibition persists, however, he emphasized in the letter that the associated “suffering, injustice, and inequity” of criminalization also linger. And that has imperiled the movement that advocates and stakeholders have worked for years to build. If the industry fails, “we fail together,” he wrote. “A strong industry creates jobs, generates tax revenues, and revitalizes local economies. These arguments were, and still are, powerful incentives for reform. But they cannot finish the job of ending prohibition. They don’t speak to the deeper issues that first brought this movement together, nor can they speak with authority to address the concerns, including public health and safety, that many lawmakers and their constituents have about cannabis.” Smith also pointed out that the prohibitionist group Smart Approaches to Marijuana (SAM) and its allies are actively “backing legislation, and soon ballot initiatives, to roll back our progress state by state.” That includes a possible 2026 ballot measure in Massachusetts to recriminalize recreational marijuana sales. Prohibitionists “also know that the normal incentives of any industry, reducing costs and maximizing profits, can undercut an industry’s credibility with lawmakers and the public on these threshold issues,” he said. “Their strategy is to force legislators into a false choice between your profit motives and their claim to the mantle of public health. They want you isolated in that fight.” “But independent advocacy requires resources. And resources have been scarce. At the Marijuana Policy Project, we have led the fight to secure 29 medical and adult-use laws, both through legislatures and ballot initiatives. We have helped ensure good faith implementation of those laws and defended them when opponents have tried to roll them back.” Smith noted that MPP is actively working to advance adult-use legalization in Louisiana, Pennsylvania and New Hampshire, and it has a “list of priorities that overlap with the industry’s across multiple legal and medical states.” “Cannabis advocacy organizations do not work for the industry, and it’s true that we will not always align or collaborate on every issue. But our independence is a feature, not a bug,” he said. “It’s what gives us credibility and increases our power over time. Anyone who wants to see sensible and lasting normalization in cannabis needs that independent power working at full strength.” There’s a “real urgency” to develop a “deeper, coordinated conversation between the leaders of industry at every level and the institutions of independent advocacy about how we move forward together,” the letter states. “That means renewed financial support, yes. But it also means better strategic alignment across our common goals and shared purpose as we confront our common challenges. Neither industry nor advocacy will succeed alone,” he said. “And maybe you didn’t even realize it was happening. So it wasn’t your responsibility to step up. But now you know. So now it is.” The post Top Marijuana Advocacy Group Urges Collaboration With Industry Amid Rise Of ‘Neo-Prohibitionist Movement’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Medical marijuana legalization is “associated with significant reductions in opioid prescribing,” yet another new study has found. Researchers at the University of Georgia and University of Colorado analyzed prescription claims for 15 to 20 million insured Americans annually from 2007-2020, comparing the prevalence of opioid prescriptions in states with and without medical cannabis programs in place. “We find that [medical cannabis laws, or MCLs] are associated with significant reductions in opioid prescribing,” the study, published in the American Journal of Health Economics, found. “Among treated states, the rate of patients receiving opioid prescriptions fell by 16% on average, masking substantial heterogeneity across states, with individual state declines reaching 22%.” “We also find significant decreases in the intensive margin, both in the daily supply and prescriptions per patient,” the researchers said. “Among subpopulations, decreases were relatively uniform across sex, age, and race/ethnicity, though cancer patients, and non-cancer Black patients experienced a larger reduction (over 20%).” The study also identified increases in the frequency of use of NSAID pain medications, “suggesting that MCLs are associated with substitution away from opioids toward safer alternatives.” “These findings support the potential of MCLs as a policy tool for reducing opioid use and promoting safer pain management,” the study authors said. “Specifically, we find a 15.8% average decrease in the rate of patients with opioid prescriptions, relative to the baseline prior to legalizing cannabis, or 107.1 fewer patients each quarter with opioids prescriptions filled per each 10,000 non-cancer enrolled patients. While all twelve MCL adopting states of our timeframe experience decreases, average results mask substantial heterogeneity across implementing states, as some state exhibit negligible decreases (e.g. Illinois), and other states show drops of over 20% in opioid prescription rates (e.g. Minnesota, New York).” The study provides one of the first estimates on the impact of medical marijuana legalization laws being adopted based on “patient level characteristics,” the researchers wrote. “We document that the decrease in opioid utilization affected most subpopulations relatively evenly, across sex, age and race/ethnicity,” the paper says. “We also document that the relative decrease among cancer patients and non-cancer black patients is larger, with drops of more than 20% on patients receiving opioid prescriptions following MCL adoption.” The researchers said their results expand on prior studies “in several important ways.” “First, our approximation allows for a greater level of heterogeneity as we document variation across states. Furthermore, we are the first study to document variation across patient characteristics as noted above. In comparison to prior estimates, our results are in line albeit slightly larger, with decreases in the rate of patients with opioid prescriptions of 15.8% following MCL adoption. Prior studies have not leverage patient-level data and are thus unable to examine changes in prescribing on the intensive and extensive margins, or examine how the availability of medical cannabis affects different patients in heterogeneous ways.” While there are certain limitations to the study, the authors said that medical marijuana legalization presents as a “valuable tool that can be used by policymakers to allow patients and physicians to reduce the prescribing of opioid analgesics.” “In addition, our results contribute to the larger discussion about the role of MCLs in pain management and how medical cannabis may be a viable alternative to riskier or more dangerous medications such as prescription opioid analgesics,” the study says. “Our findings suggest that NSAID use increased after MCL adoption, consistent with complementary use alongside medical cannabis.” “This study provides robust evidence that the adoption of MCLs is associated with significant reductions in opioid prescribing among commercially insured populations. Using a rich dataset of 15 to 20 million commercially insured individuals per year from 2007 to 2020 and a state-specific synthetic control design, we find that MCLs reduce the rate of patients receiving opioid prescriptions by approximately 16% (p= 0.0000) on average across treated states. Reductions are also evident at the intensive margin: patients receive fewer prescriptions and shorter opioid supplies per prescription.” “Importantly, these effects are present in nearly all states, they are statistically significant in many states, and they are robust to a variety of sensitivity checks, including different inference strategies (placebo or cross-validation) or alternative policy timing definitions,” it continues. “Opioid reductions were widespread across demographic subgroups but especially pronounced among cancer patients and non-cancer Black patients, where reductions in the opioid prescription rate were larger than 20%. We also find suggestive evidence of substitution toward non-opioid alternatives: NSAID prescriptions per patient rose modestly, particularly among racial/ethnic minorities. These results underscore that MCLs may support safer pain management strategies and that their effects differ by implementing state, and to a lesser extent across patient characteristics.” In August, meanwhile, Australian researchers published a separate study similarly showing that marijuana can serve as an effective substitute for opioids in pain management treatment. Another study published earlier this year in the journal Drug and Alcohol Review found that, among drug users who experience chronic pain, daily cannabis use was linked to a higher likelihood of quitting the use of opioids—especially among men. Research published late last year also found that legalizing medical cannabis appeared to significantly reduce monetary payments from opioid manufacturers to doctors who specialize in pain, with authors finding “evidence that this decrease is due to medical marijuana becoming available as a substitute” for prescription painkillers. Other recent research also showed a decline in fatal opioid overdoses in jurisdictions where marijuana was legalized for adults. That study found a “consistent negative relationship” between legalization and fatal overdoses, with more significant effects in states that legalized cannabis earlier in the opioid crisis. Authors estimated that recreational marijuana legalization “is associated with a decrease of approximately 3.5 deaths per 100,000 individuals.” “Our findings suggest that broadening recreational marijuana access could help address the opioid epidemic,” that report said. “Previous research largely indicates that marijuana (primarily for medical use) can reduce opioid prescriptions, and we find it may also successfully reduce overdose deaths.” Another recently published report into prescription opioid use in Utah following the state’s legalization of medical marijuana found that the availability of legal cannabis both reduced opioid use by patients with chronic pain and helped drive down prescription overdose deaths statewide. Overall, results of the study indicated that “cannabis has a substantial role to play in pain management and the reduction of opioid use,” it said. Yet another study, published in 2023, linked medical marijuana use to lower pain levels and reduced dependence on opioids and other prescription medications. And another, published by the American Medical Association (AMA) last February, found that chronic pain patients who received medical marijuana for longer than a month saw significant reductions in prescribed opioids. About one in three chronic pain patients reported using cannabis as a treatment option, according to a 2023 AMA-published report. Most of that group said they used cannabis as a substitute for other pain medications, including opioids. Other research published that year found that letting people buy CBD legally significantly reduced opioid prescription rates, leading to 6.6 percent to 8.1 percent fewer opioid prescriptions. A 2022 research paper that analyzed Medicaid data on prescription drugs, meanwhile, found that legalizing marijuana for adult use was associated with “significant reductions” in the use of prescription drugs for the treatment of multiple conditions. A 2023 report linked state-level medical marijuana legalization to reduced opioid payouts to doctors—another datapoint suggesting that patients use cannabis as an alternative to prescription drugs when given legal access. Researchers in another study, published last year, looked at opioid prescription and mortality rates in Oregon, finding that nearby access to retail marijuana moderately reduced opioid prescriptions, though they observed no corresponding drop in opioid-related deaths. Other recent research also indicates that cannabis may be an effective substitute for opioids in terms of pain management. A report published recently in the journal BMJ Open, for instance, compared medical marijuana and opioids for chronic non-cancer pain and found that cannabis “may be similarly effective and result in fewer discontinuations than opioids,” potentially offering comparable relief with a lower likelihood of adverse effects. Separate research published found that more than half (57 percent) of patients with chronic musculoskeletal pain said cannabis was more effective than other analgesic medications, while 40 percent reported reducing their use of other painkillers since they began using marijuana. The post Legalizing Medical Marijuana Leads To ‘Significant Reductions’ In Opioid Prescriptions, Another Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“Today’s decision allows thousands of hardworking Ohio entrepreneurs to continue supporting their families and serving consumers who rely on access to safe, legal, and properly regulated hemp products.” By Megan Henry, Ohio Capital Journal Ohio stores can temporarily resume to selling intoxicating hemp products—for now. Franklin County Court of Common Pleas Judge Carl Aveni granted a 14-day temporary restraining order on Gov. Mike DeWine’s (R) executive order banning the sale of intoxicating hemp products on October 14. DeWine announced last week a 90-day executive order that bans the sale of intoxicating hemp products that also started on October 14. The next hearing in this case is scheduled for October 28. Intoxicating hemp products are items that contain THC that are sold anywhere other than licensed marijuana dispensaries including gas stations, smoke shops and CBD stores, among others. Marijuana is not considered an intoxicating hemp product and is legal in Ohio. This ban does not affect the marijuana law passed by voters in 2023. “While we continue to fight in court, today’s developments underscore our continued desire to work with the General Assembly to pass permanent legislation regarding intoxicating hemp,” DeWine said in a statement. Titan Logistic Group, Fumee Smoke and Vape and Invicta Partners—all members of the Ohio Healthy Alternatives Association—filed a lawsuit last week against the ban, arguing DeWine is breaking federal and state law by restricting access to these products. “Today’s decision allows thousands of hardworking Ohio entrepreneurs to continue supporting their families and serving consumers who rely on access to safe, legal, and properly regulated hemp products,” Ohio Healthy Alternatives Association said in a statement. The 2018 Farm Bill says hemp can be grown legally if it contains less than 0.3 percent THC. “The Executive Order is overly broad in that it applies to all hemp and hemp products including those that are legal under the 2018 Farm Bill and Ohio’s current laws,” the lawsuit says. “It is also vague because there is no definition of ‘intoxicating hemp’ in the Ohio Revised Code or Ohio Administrative Code.” DeWine—who has been calling on lawmakers to regulate or ban delta-8 THC products since January 2024—spent much of last week’s press conference where he announced the ban talking about the need to protect children from these products. Ohio voters have opined on where they want cannabis sold by their passage of Issue 2, which passed with the support of 57% of Ohio voters. Issue 2 limited the sale of cannabis to dispensaries. The sale of cannabis as intoxicating hemp in these other venues was never… — Governor Mike DeWine (@GovMikeDeWine) October 14, 2025 It was reported in January 2024 that there had been at least 257 reports of delta-8 poisoning in Ohio in recent years—including 102 in 2023 and 40 that involved children under six-years-old, according to the Ohio Poison Control Center. The plaintiffs, however, disagree. “Governor DeWine lacks a basis to use an executive order to regulate all hemp products because there is no evidence hemp products pose an imminent threat to public health,” the lawsuit reads. Ohio has more than 4,000 small businesses and family-owned businesses that sell hemp products, according to the lawsuit. The Ohio Capital Journal talked to people in the hemp industry who were worried what DeWine’s ban would mean for their businesses and customers. Hemp products account for all of Titan’s sales and they will be forced to close if the ban goes into effect, according to the court documents. Approximately 25 percent of Fumee’s sales are hemp products and they expect to fire half of their staff if the ban takes place, according to the court documents. “Governor DeWine’s order was not only unlawful—it was an abuse of executive authority that threatened to devastate an entire sector overnight,” Dakota Sawyer of American Republic Policy said in a statement. “Today’s decision restores sanity and due process.” Jim Higdon, co-founder of Cornbread Hemp in Kentucky, which sells its products in more than 300 Ohio retail stores, said the judge’s ruling was a win for Ohio. “By granting the TRO, the court recognized that Governor DeWine’s reckless executive order should not take effect without proper legislative debate and due process,” Higdon said in a statement. “This decision protects adult Ohioans’ access to federally legal hemp products and sends a clear message to the legislature that it must act.” There are a handful of bills in the Ohio legislature that would regulate intoxicating hemp products in various ways. At least 32 states have some regulations on intoxicating hemp products. This story was first published by Ohio Capital Journal. Photo elements courtesy of rawpixel and Philip Steffan. The post Ohio Judge Blocks Governor’s Hemp Product Ban From Taking Effect appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

It’s a “more accessible purchasing option for medical patients, primary caregivers and consumers, particularly those with physical limitations.” By Rebecca Rivas, Missouri Independent Missouri marijuana dispensaries may soon be able to offer curbside pickup, which would add to the drive-thru and delivery services already allowed with state approval. The Missouri Division of Cannabis Regulation published a draft of a proposed amendment to allow curbside pickup at dispensaries on Tuesday and is asking for public feedback until October 28. Mark Hendren, president of Flora Farms cannabis company, said the change would help his three dispensary locations that don’t currently offer drive-thru services. The other five Flora Farm locations already have drive-thrus. “When a customer comes in, they have to physically get out and come into the facility and go through the normal check-in process,” Hendren said. “And for some of our customers that are disabled, that’s a burden.” According to the rule draft, customers would pay for the products online so no cash is exchanged outside the facility in the pickup location. The pickup site would need the same video camera monitoring and recording the drive-through lanes currently have. The dispensaries would need to post a sign, stating: “It is against the law to operate a dangerous device, motor vehicle, aircraft, or motorboat while under the influence of marijuana,” according to the draft. The draft released Tuesday is not part of a formal rulemaking process, according to a press release by the Missouri Department of Health and Senior Services, which oversees the division. It’s “instead part of DHSS’ ongoing efforts to gather all relevant input before formally filing proposed rules and proposed changes to rules,” the press release states. The proposed amendment is designed to improve cannabis licensee operations by, “offering a more accessible purchasing option for medical patients, primary caregivers and consumers, particularly those with physical limitations,” it states. The rule and online suggestion forms can be found on the DHSS Pre-Rulemaking Feedback page. This story was first published by Missouri Independent. The post Missouri Marijuana Dispensaries Could Offer Curbside Pickup Under New Rules Proposed By State Officials appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Awesome posting, it has the such a interesting site there is listed here, keep up to date favorable deliver the results, might be backside. olxtoto Whoa! Precisely what a close look opener this specific article have been to me. A lot loved, added, My spouse and i can’t loose time waiting for additional! bandar togel Excellent content, the country's an exceedingly cold web page you've got right, preserve acknowledge that there are succeed, would be lower back. situs toto I simply reckoned it is an outline to share in case other companies was first experiencing difficulty looking for still Now i'm a small amount of doubting generally if i here's permitted to use artists and additionally explains relating to right. slot depo 5k Good publish, it's a very awesome weblog you have right here, continue the great function, is going to be back again. Gouri

A U.S. Department of Veterans Affairs (VA) official says the federal government needs to “gear up” to provide psychedelic medicines to veterans and ensure that therapists are equipped to facilitate the novel therapy. As VA continues to support research into psychedelic medicine, Rachel Yehuda, director of mental health at VA’s James J. Peters Veterans Affairs Medical Center, spoke on CBS Mornings on Friday about the therapeutic potential of substances such as psilocybin and MDMA for veterans. “There’s still a lot more research that needs to be done, and we have to gear up in a way that makes it safe to be able to provide these therapies,” she said. “We have to make sure therapists know how to use these medications—and also who should and shouldn’t be treated with them.” The widespread piecemeal approach to mental health treatment for conditions such as depression, anxiety and trauma is simply a means of dampening “symptoms,” rather than identifying possible cures, she said. Psychedelics represent “a very different approach.” “This is an approach where you take a medication that puts you in an altered state of consciousness—and if you are prepared for it in the right way, and you do it in the right setting with the right facilitator, different kind of material will surface,” Yehuda, who was speaking in the interview in her capacity as director of Mount Sinai’s Parsons Research Center for Psychedelic Healing and not appearing as a representative of VA, said. “Emotions, thoughts, memories—a lot of things that usually you spend a lot of time keeping down.” “But the reason that we have mental health symptoms is because we feel those things and because things have happened to us,” Yehuda said. “So this is a way to access and be able to work with really what’s at the core of the problem.” “This is a way of taking a medicine—a medication once or twice or three times at most—these are sessions that take several hours with psilocybin or MDMA [and] could be six or eight hours, and you’re with therapists the whole time,” she said. “Stuff comes up that you talk about, and hopefully you won’t have to keep taking medications once you try to get at the root of the problem.” “But let’s be very clear that there is a danger in having unfettered access to psychedelics and having people—I wouldn’t say danger, the drugs themselves are not very dangerous—but the material that can surface with these drugs can be very overwhelming. So you want to really make sure that you take the drug with a professional who is able to help you make meaning out of the experience that you’ve just had. For many people, what comes up can be very overwhelming, and if they don’t have somebody there to talk them through it, then maybe some things can happen that would be harmful.” “I think that really, when we’re talking about what’s new in the field of mental health, we are not talking about handing somebody a psychedelic and saying, ‘let me know how it goes,'” she said. “We’re talking about a supervised experience.” Yehuda has routinely discussed the therapeutic potential of psychedelic medicine with respect t0 veterans with conditions such as post-traumatic stress disorder (PTSD). — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, former U.S. House Speaker Newt Gingrich (R-GA) over the summer extolled the therapeutic promise of ibogaine on an episode of his podcast, drawing attention to a Stanford University study that found the psychedelic showed potential to treat PTSD, anxiety and depression in military veterans with traumatic brain injury. The message around the therapeutic potential of psychedelics has been getting out in a number of ways, including in prominent conservative media circles and within the Trump administration. For example, a Navy SEAL veteran credited with killing Osama Bin Laden said during a Fox News interview that psychedelic therapy has helped him process the trauma he experienced during his time in the military, stressing that “it works” and should be an available treatment option. That interview came days after the U.S. House of Representatives included an amendment to a spending bill from Reps. Lou Correa (D-CA) and Jack Bergman (R-MI) that would encourage VA to support research into the benefits of psychedelics in treating medical conditions commonly affecting military veterans. Meanwhile, HHS Secretary Kennedy recently said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.” VA Secretary Doug Collins also disclosed in April that he had an “eye-opening” talk with Kennedy about the therapeutic potential of psychedelic medicine. And he said he’s open to the idea of having the government provide vouchers to cover the costs of psychedelic therapy for veterans who receive services outside of VA as Congress considers pathways for access. Collins also recently visited a facility conducting research on psychedelics, and he reiterated that it’s his “promise” to advance research into the therapeutic potential of the substances—even if that might take certain policy changes within the department and with congressional support. The secretary’s visit to the psychedelics research center came about a month after the VA secretary met with a military veteran who’s become an advocate for psilocybin access to discuss the therapeutic potential of psychedelic medicine for the veteran community. Collins also briefly raised the issue in a Cabinet meeting with President Donald Trump in April. Correa and Bergman—co-chairs of the Congressional Psychedelic Advancing Therapies (PATH) Caucus—introduced a bill in April to provide $30 million in funding annually to establish psychedelics-focused “centers for excellence” at VA facilities, where veterans could receive novel treatment involving substances like psilocybin, MDMA and ibogaine. Bergman has also expressed optimism about the prospects of advancing psychedelics reform under Trump, arguing that the administration’s efforts to cut spending and the federal workforce will give agencies “spines” to tackle such complex issues. Kennedy, for his part, also said in April that he had a “wonderful experience” with LSD at 15 years old, which he took because he thought he’d be able to see dinosaurs, as portrayed in a comic book he was a fan of. Last October, Kennedy specifically criticized FDA under the prior administration over the agency’s “suppression of psychedelics” and a laundry list of other issues that he said amounted to a “war on public health” that would end under the Trump administration. In December, VA separately announced that it’s providing $1.5 million in funding to study the efficacy of MDMA-assisted therapy for veterans with PTSD and alcohol use disorder (AUD). In January, former VA Under Secretary for Health Shereef Elnahal said that it was “very encouraging” that Trump’s pick to have Kennedy lead HHS has supported psychedelics reform. And he hoped to work with him on the issue if he stayed on for the next administration, but that didn’t pan out. Photo courtesy of Dick Culbert. The post VA Official Says Federal Government Must ‘Gear Up’ For Expanding Psychedelic Medicine For Veterans appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

his really is therefore stunning as well as innovative. I simply adore the actual colours as well as whomever will get this within the postal mail is going to be grinning. olxtoto When i got onto your blog site though putting attention simply just a little bit submits. Pleasant strategy for future, I will be bookmarking at a time get ones finish springs up. bandar togel Terrific put up, attended on top not to mention saved your web sites. I just can’t hang around to study further because of most people. situs toto When i stunned while using the research people meant to makes unique post awesome. Superb pastime! slot gacor The item senses brilliant to learn to read like beneficial in addition to one of a kind articles or blog posts with your internet websites. selatox before and after

Oklahoma activists are in the “home stretch” to collect enough signatures to put a marijuana legalization initiative on the state’s 2026 ballot, with just under three weeks left to go before a critical deadline. Key to the campaign’s signature gathering operation are partnerships with retailers across the state—from existing medical cannabis dispensaries to tattoo parlors—that are carrying the petitions. Jed Green, founder of Oklahomans for Responsible Cannabis Action (ORCA), tells Marijuana Moment that there are now more than 500 locations lending their support by serving as signing locations. “A lot of folks are doubling down on their efforts,” he said. “We’re hoping to be able to do some things to try to drive voter and consumer traffic to those locations, as well as get out to a lot of the public events that happen in the fall. So we’ve been out working on those as well.” ORCA will need to submit the required 172,993 signatures by November 3, after which point the secretary of state’s office will need to validate them. Then there will be a 90-day window for any legal challenges to the measure. If the campaign clears that barrier, it will appear on the ballot. While the campaign hasn’t been actively verifying signatures it’s collected so far due to the “decentralized” nature of the effort, with a largely volunteer base of petitioners and retail partners, Green said “we’ve got some pretty big piles” of signed petitions on hand at this point. View full screen map “Simply put, as we enter into the home stretch, it’s vital that our people reach out to their friends, to their family, and simply work to get everyone together,” he said. “We know that we have the votes here. It’s simply the logistical lift of getting them all together. So the more folks can do to reach out to their family and friends, get them to sign, the better off we’ll be.” The turnaround to get the signatures delivered is tight, as the campaign only started collecting them in August and is quickly approaching the early November turn-in deadline. There are challenges unique to this election cycle, as earlier this year Gov. Kevin Stitt (R) gave final approval to legislation that some advocates worry will inhibit future citizen-led policy changes, including cannabis reform. The law puts additional requirements on initiative “gist” language that voters see on the ballot and also revise policies around signature gathering to make it so petitioners could only submit signatures from up to 11.5 percent of registered voters in a single county for statutory proposals and 20.8 percent for constitutional measures. The law is currently being litigated for reasons unrelated to the specific cannabis proposal. Green previously said that one of the key differences between the initiative his organization is pushing and a previous one that failed at the ballot in 2023 is that it accounts for concerns about licensing rules. Many have criticized the rollout of the state’s medical marijuana law, which led to a dramatic proliferation of dispensaries, and Green said the failed adult-use measure effectively duplicated that licensing scheme. Here’s what ORCA’s latest marijuana legalization initiative would accomplish: It would allow adults 21 and older to purchase and possess up to eight ounces of cannabis for personal use. They could also grow up to 12 plants and possess what’s harvested, and they would be able to have up to one ounce of cannabis concentrates. The proposed constitutional amendment would also provide that Oklahoma banks would not be penalized simply for servicing state-licensed cannabis businesses. Further, the initiative includes protections to make it so any adults would be shielded from being penalized with respect to “healthcare, housing, employment, public assistance, public benefit, parental right, educational opportunity, extracurricular activity” and also “licensure or licensed activity” such as firearm ownership and driving rights due to any legal cannabis activity. As part of those protections, the presence of THC metabolites in a person’s system could not be used as evidence of impairment. Local governments would not be permitted to impose bans on the marijuana home cultivation, and any regulations they set on the activity could not be “unduly burdensome.” Additionally, no public ordinances on public smoking for marijuana could be more restrictive than what’s currently in place for tobacco. Existing medical cannabis dispensaries, as well as any new retail licensees, would be able to start selling to adult consumers starting 60 days after the measure’s enactment. After 180 days, they could start delivering cannabis products to adults. The same state departments that oversee the current medical cannabis program would be responsible for regulate the adult-use market. A 10 percent excise tax would be imposed on adult-use marijuana products, and the initiative stipulates that the legislature would be empowered to decrease that tax rate but not raise it. Revenue from those tax dollars would go toward the state general fund (40 percent), as well as county governments (30 percent) and municipal governments (30 percent) where retail sales occurred. For unincorporated jurisdictions, revenue would be split evenly, with 5o percent for the general fund and 50 percent for the counties. Sixty days after the measure’s enactment, the tax rate on marijuana for registered cannabis patients would be eliminated. It also states that state-licensed marijuana businesses couldn’t be prevented from engaging in interstate commerce if there’s a change in federal law, or a court action, permitting such activity. If that happens, the legislature would be authorized to place up to a 3 percent wholesale tax on cannabis exported beyond state lines. As Oklahoma activists work to collect signatures, meanwhile, law enforcement leaders with the Oklahoma Association of Chiefs and Oklahoma Bureau of Narcotics and Dangerous Drugs have been raising concerns about cannabis. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Oklahoma, lawmakers in March advanced a bill aimed at protecting gun rights of state-registered medical marijuana patients, although federal law still bars cannabis users from owning firearms regardless of their patient status. Another state bill filed in January by a GOP legislator would criminalize the use of medical cannabis during pregnancy. Photo courtesy of Chris Wallis // Side Pocket Images. The post Oklahoma Marijuana Campaign In ‘Home Stretch’ For 2026 Legalization Initiative, With Under Three Weeks To Collect Signatures appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I’ve been searching for some decent stuff on the subject and haven't had any luck up until this point, You just got a new biggest fan!.. why is robert peston not on tv tonight

SCOTUS acts on marijuana & guns case; CA gov vetoes cannabis shipping bill; NC psychedelics; Study: Blunt smoking on the rise; OH hemp THC product ban Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Hold on, just one second before you read today’s news. Have you thought about giving some financial support to Marijuana Moment? If so, today would be a great day to contribute. We’re planning our reporting for the coming months and it would really help to know what kind of support we can count on. Check us out on Patreon and sign up to give $25/month today: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Sen. Thom Tillis (R-NC) told Marijuana Moment that it’s time to create a federal “regulatory construct” for cannabis “where you have excise taxes, you have money flowing to law enforcement and other agencies and then have Congress have a simple up or down vote on it.” The U.S. Supreme Court narrowed its list of pending cases concerning the federal ban on gun ownership by marijuana consumers as the justices declined to take up one of about a half dozen—with the others now set to be discussed at a meeting on Friday. California Gov. Gavin Newsom (D) vetoed a bill that would have allowed certain marijuana microbusinesses to ship medical cannabis products directly to patients via common carriers like FedEx and UPS. Bipartisan North Carolina lawmakers spoke about the therapeutic benefits of psychedelics for military veterans—with a Republican senator saying the state could “lead the nation” on the issue. A new study found that marijuana “blunt smoking increased substantially from 2015 to 2022” in the U.S.—with much of the rise from “groups with historically lower use rates” such as women, older people and those who do not drink alcohol. As an executive order from Ohio Gov. Mike DeWine (R) temporarily banning intoxicating hemp products takes effect, business owners are worried the policy will negatively impact their employees and customers. / FEDERAL The U.S. government reportedly revoked visas of at least 50 Mexican politicians and government officials amid the Trump administration’s crackdown on drug cartels and their suspected political allies. Sen. Elissa Slotkin (D-MI) said there are “a lot of folks who own firearms and smoke marijuana.” / STATES Michigan Gov. Gretchen Whitmer (D) said she is “sympathetic” to the cannabis industry’s concerns about a new wholesale tax. Arkansas’s finance secretary told lawmakers that regulators are in no rush to award final medical cannabis dispensary licenses. A Pennsylvania senator tweeted, “Two things I think @realDonaldTrump will do before the midterms, reschedule cannabis, and fix our broken health insurance system.” Washington, D.C.’s top medical cannabis regulator discussed efforts to enforce laws against unregulated businesses selling marijuana, psychedelics and other drugs. California regulators adopted changes to cannabis tax rules. Missouri regulators published draft changes to rules on marijuana dispensary licenses. The New York Cannabis Advisory Board an initial round of grants to organizations serving communities impacted by marijuana arrests. Vermont regulators suspended the license of a cannabis business. Oregon regulators will consider changes to marijuana and hemp rules on Thursday. Nevada regulators will consider cannabis business issues on Thursday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Boston, Massachusetts Cannabis Board will meet on October 22. / SCIENCE & HEALTH A study of mice suggested that “cannabinoid administration has the potential to be an effective alternate therapeutic option for [ulcerative colitis] management.” A study examined “factors influencing nonprofit responses to cannabis industry philanthropy.” / ADVOCACY, OPINION & ANALYSIS The leader of the Scottish Labour Party discussed his opposition to decriminalizing drugs. / BUSINESS Glass House Brands Inc. began trading on the Robinhood platform. Tilray Medical is expanding its medical cannabis operations into Panama. Curaleaf Holdings, Inc. entered into an amended and restated agreement with Needham Bank to expand the borrowing capacity of its revolving credit facility from $40 million to $100 million and extend the maturity to up to five years. Missouri retailers sold $118.9 million worth of legal marijuana products in September. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post GOP senator pushes federal cannabis “regulatory construct” (Newsletter: October 15, 2025) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

It's great to see the cannabis community rallying together for fair treatment on platforms like Instagram! I fully support WeedTube's initiative to end the unfair censorship surrounding legal cannabis content. It's crucial for small businesses to have the same opportunities as larger corporations. As we advocate for change, it's a reminder of how diverse and engaging online platforms can be—much like exploring new worlds in games like Solar Smash. Let's keep the conversation going!